2-甲基-5-[3-[3-[4-(甲基亚磺酰基)苯基]-5-苯并呋喃基]-1,3,4-恶二唑 | 1005201-24-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 2-甲基-5-[3-[3-[4-(甲基亚磺酰基)苯基]-5-苯并呋喃基]-1,3,4-恶二唑
• 英文名称: TCS2002
• 英文别名: 2-methyl-5-{3-[4-(methylsulfinyl)phenyl]-1-benzofuran-5-yl}-1,3,4-oxadiazole；1,3,4-Oxadiazole, 2-methyl-5-[3-[4-(methylsulfinyl)phenyl]-5-benzofuranyl]-；2-methyl-5-[3-(4-methylsulfinylphenyl)-1-benzofuran-5-yl]-1,3,4-oxadiazole
• CAS: 1005201-24-0
• 化学式: C₁₈H₁₄N₂O₃S
• 分子量: 338.387
• InChiKey: RCKYSTKYIVULEK-UHFFFAOYSA-N

物化性质

• 沸点：
  579.0±60.0 °C(Predicted)
• 密度：
  1.43±0.1 g/cm3(Predicted)
• 溶解度：
  <33.84mg/ml，溶于DMSO； <8.46mg/ml，在乙醇中

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  88.3
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-甲基-5-[3-[3-[4-(甲基亚磺酰基)苯基]-5-苯并呋喃基]-1,3,4-恶二唑 在 2,6-二甲基吡啶 、 三氟乙酸酐 、 盐酸 、 三乙胺 、 丁酰氯 作用下， 以 二氯甲烷 、 甲醇 为溶剂， 反应 13.0h， 以13%的产率得到2-methyl-5-[3-(4-thiophenyl)-1-benzofuran-5-yl]-1,3,4-oxadiazole
  参考文献：
  名称：

  Radiosynthesis and preliminary PET evaluation of glycogen synthase kinase 3β (GSK-3β) inhibitors containing [11C]methylsulfanyl, [11C]methylsulfinyl or [11C]methylsulfonyl groups

  摘要：

  Three compounds 1-3 containing methyl-sufanyl, sufinyl, or sulfonyl groups are strong inhibitors of glycogen synthase kinase 3 beta (GSK-3 beta), an enzyme associated with Alzheimer's disease. We labeled 1-3 with C-11 for a positron emission tomography (PET) brain imaging study. A novel thiophenol precursor 4 for radiosynthesis was prepared by reacting sulfoxide 2 with trifluoroacetic anhydride. [C-11]1 was synthesized by reacting 4 with [C-11] methyl iodide in 52 +/- 5% radiochemical yield (n = 5, based on [C-11]CO2, corrected for decay). Oxidation of [C-11]1 with Oxone (R) produced [C-11]2 and [C-11]3, respectively. PET with [C-11]1 and [C-11]3 showed 2 fold higher brain uptake of radioactivity in a mouse model of cold water stress in which GSK-3b expression was increased, than in the controls. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.05.085
• 作为产物：
  描述：

  2-methyl-5-{3-[4-(methylsulfanyl)phenyl]-1-benzofuran-5-yl}-1,3,4-oxadiazole 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 0.08h， 以84%的产率得到2-甲基-5-[3-[3-[4-(甲基亚磺酰基)苯基]-5-苯并呋喃基]-1,3,4-恶二唑
  参考文献：
  名称：

  GSK-3BETAINHIBITOR

  摘要：

  为了提供一种含有噁二唑化合物或其盐或其前药的GSK-3β抑制剂，用作GSK-3β相关病理或疾病的预防或治疗剂，本发明提供了一种含有由以下式（I）表示的化合物的GSK-3β抑制剂： 其中每个符号如规范中定义，或其盐或其前药。

  公开号：

  US20100069381A1

文献信息

• GSK-3BETAINHIBITOR
  申请人：Itoh Fumio

  公开号：US20100069381A1

  公开（公告）日：2010-03-18

  For the purpose of providing a GSK-3β inhibitor containing an oxadiazole compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3β-related pathology or disease, the present invention provides a GSK-3β inhibitor containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

  为了提供一种含有噁二唑化合物或其盐或其前药的GSK-3β抑制剂，用作GSK-3β相关病理或疾病的预防或治疗剂，本发明提供了一种含有由以下式（I）表示的化合物的GSK-3β抑制剂： 其中每个符号如规范中定义，或其盐或其前药。
• GSK-3β inhibitor
  申请人：Itoh Fumio

  公开号：US08492378B2

  公开（公告）日：2013-07-23

  For the purpose of providing a GSK-3β inhibitor containing an oxadiazole compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3β-related pathology or disease, the present invention provides a GSK-3β inhibitor containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

  为了提供一种含有噁唑烷化合物或其盐或前药的GSK-3β抑制剂，该抑制剂可用作GSK-3β相关病理或疾病的预防或治疗剂，本发明提供了一种包含式（I）所表示的化合物的GSK-3β抑制剂：其中每个符号如规范中所定义，或其盐或前药。
• METHOD OF TREATMENT OF PARKINSONISM
  申请人：Fundacio Centre de Regulacio Genomica

  公开号：EP3231434A1

  公开（公告）日：2017-10-18

  The invention relates to a cell selected from the group consisting of a hematopoietic stem cell (HSC), a hematopoietic progenitor cell (HPC), and a mesenchymal stem cell (MSC), or a cell population comprising any combination thereof, for use in the treatment of Parkinsonism in a subject, and to pharmaceutical compositions and kits for use in the treatment of Parkinsonism.

  本发明涉及一种选自造血干细胞（HSC）、造血祖细胞（HPC）和间充质干细胞（MSC）组成的组的细胞，或由其任意组合而成的细胞群，用于治疗受试者的帕金森病，还涉及用于治疗帕金森病的药物组合物和试剂盒。
• Compositions and methods for epithelial stem cell expansion and culture
  申请人：The Brigham and Women's Hospital, Inc.

  公开号：US10041046B2

  公开（公告）日：2018-08-07

  Described are cell culture solutions and systems for epithelial stem cell and organoid cultures, formation of epithelial constructs and uses of the same in transplantation. A single layer of epithelial cells that actively self-renews and is organized into crypts and villi clothes the intestine. It has been recently shown that the renewal of intestinal epithelium is driven by Lgr5+ intestinal stem cells (ISC) that reside at the base of these crypts (Barker et al., 2007). Lgr5+ stem cells can be isolated and cultured in vitro to form organoids containing crypt-vcllus structures that recapitulates the native intestinal epithelium (Sato et al., 2009).

  描述了用于上皮干细胞和类器官培养的细胞培养液和系统、上皮构建体的形成及其在移植中的应用。上皮细胞是一种单层上皮细胞，能主动自我更新，并被组织成隐窝和绒毛，为肠道穿衣。最近的研究表明，肠上皮细胞的更新是由位于这些隐窝底部的Lgr5+肠干细胞（ISC）驱动的（Barker等人，2007年）。Lgr5+干细胞可被分离出来并在体外培养，形成含有隐窝-绒毛结构的器官组织，从而再现原生肠上皮（Sato等人，2009年）。
• Derivation of hepatic stem cells and mature liver cell types and uses thereof
  申请人：AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

  公开号：US10683484B2

  公开（公告）日：2020-06-16

  This application describes liver stem cells (LSC), and differentiated hepatocytes, cholangiocytes, and 3D cellular structures derived therefrom. Methods for producing LSC and mature, differentiated hepatocytes and cholangiocytes in culture are provided. Also provided are cell culture systems and cell culture media for producing a homogenous population of liver stem cells that remain in an undifferentiated state over multiple passages in culture. The LSC and methods are useful for producing homogenous populations of hepatocytes and cholangiocytes for downstream applications. The LSC can be transplanted into subjects to treat liver diseases.

  本申请介绍了肝干细胞（LSC）、分化的肝细胞、胆管细胞以及由此衍生的三维细胞结构。本申请提供了在培养过程中产生 LSC 以及成熟、分化的肝细胞和胆管细胞的方法。此外，还提供了细胞培养系统和细胞培养基，用于产生在培养过程中多次传代保持未分化状态的同源肝干细胞群。这种肝干细胞和方法可用于生产下游应用所需的同源肝细胞和胆管细胞。肝干细胞可移植到受试者体内治疗肝脏疾病。